Research - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read nowInsights - A draft of the 21st Century Cures Act carries serious implications for biopharma. Longer exclusivity, a faster approval process, and even the chance to SELL some exclusivity for certain products.
Read nowResearch - We see uniQure (QURE) as a dark horse in gene therapy, in-part because of numerous catalysts in 2015 that will put fresh eyes on this European company.
Read nowResearch - This is the first clinical step for “new Tekmira”. Announced last week, Tekmira is merging with OnCore Biopharma to focus on therapeutics for Hepatitis B.
Read nowResearch - By Zack Fink and guest contributor Dan Marks Bluebird bio (BLUE) will release data from the first Sickle Cell Disease patient treated with its LentiGlobin gene therapy … Continue Reading
Read nowInsights - 2014 was a stellar year in biotech, for investors as well as patients. Here’s to an even better 2015. Happy new year! At PropThink, our goal has always … Continue Reading
Read now
